Navigation Links
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Date:8/17/2009

Cetrorelix pamoate is currently in three Phase 3 trials involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe.

The first Phase 3 efficacy trial Z-033, titled, "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1-year placebo-controlled efficacy study and long-term safety assessment", involved 667 patients mostly in North America and assessed an intermittent dosage regimen of cetrorelix as treatment for BPH-related signs and symptoms.

As announced recently, patients completing the 52 week double-blind study are then allowed to continue into an open-label extension of this study, sponsored by sanofi-aventis, where patients receive the same dosing regimen of cetrorelix by IM injection at Week 52, 54, 78 and 80, and are followed up to Week 90. Patients entering this extension study will be followed-up for safety, IPSS and quality of life, thus providing follow-up data on cetrorelix for up to 5 years.

The second multi-center Phase 3 efficacy study Z-036 for which patient recruitment was completed in October 2008, involves 420 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, M.D., of the Andros Mannenkliniek, Arnhem, The Netherlands, receive cetrorelix according to similar dosing regimens used in the first efficacy study Z-033.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include changes in sexual function. Other important endpoints include plasma changes in levels of testosterone, and assessment of other adverse events.

The third trial of the program is the safety study Z-041 titled, "Cet
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
2. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
3. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
6. AEterna Zentaris Receives US$10 Million from Institutional Investors
7. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
8. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
10. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
11. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... -- Research and Markets  has announced the addition ... Gas Chromatograph Market by Type , Technology, Spectroscopy, Gas ... Forecast to 2013 - 2020" report to their ... process analytical instrument that provides chemical composition data on ... by which companies carry out their production and improve ...
(Date:9/29/2014)... 29, 2014 Burnham Securities Inc. ("Burnham"), ... ("TCG"), a leader in healthcare venture development and ... alliance to expand the range of services each ... alliance, Burnham Securities will be supported by a ... and management in healthcare industry to build a ...
(Date:9/29/2014)... , September 29, 2014 ... for severe infections, today announced that the Biomedical Advanced ... Atox Bio with a contract valued up to $24 ... to treat Necrotizing Soft Tissue Infections (NSTI) and potentially ... end in sepsis. BARDA awarded the contract ...
(Date:9/29/2014)... (PRWEB) September 29, 2014 Westbridge ... SUPPRESS™ Herbicide EC, a highly effective new tool ... as a broad spectrum contact herbicide for post-emergent, ... food and non-food crops. The formulation is an ... Organic Materials Review Institute (OMRI) for use in ...
Breaking Biology Technology:Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2Westbridge Receives EPA Approval for Its New SUPPRESS™ Herbicide EC 2
... , , , , ... drugs to combat Alzheimer,s began journey 8 years ago , , ... of a million" , , NEW YORK, Aug. 6 ... (ADDF) , have achieved a significant milestone in their development as they advance ...
... UMEA, Sweden, August 6 Omnio Healer AB, ... anti-infection, today,announced that it has entered into a partnership ... provide process,development and cGMP production services relating to Omnio ... Based on a novel therapeutic concept for wound healing ...
... , WALTHAM, Mass., Aug. 6 Interleukin ... today that it will host a conference call and webcast on ... Company,s business developments and second quarter financial results. , , ... 719-325-4847 (international). The live webcast and replay access of the teleconference ...
Cached Biology Technology:PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan 2PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan 3Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments 2Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments 3
(Date:9/29/2014)... September 29: Between 1970 and 2010 populations of ... globe dropped 52 percent, says the 2014 Living ... (WWF). This biodiversity loss occurs disproportionately in low-income ... high-income countries. , In addition to the precipitous ... to other warning signs about the overall health ...
(Date:9/29/2014)... with children at home should use ventilation when cooking ... are recommending, after a new study showed an association ... and chronic bronchitis. , "In homes where a gas ... and wheezing is higher than in homes where a ... an associate professor in the College of Public Health ...
(Date:9/29/2014)... bad rap, and understandably so. The grain-of-rice-sized insects are ... of acres in the Western U.S. and Canada over ... belief, these pests may not be to blame for ... through the region. Instead, weather and topography play a ... these bark-boring beetles. , New research led by the ...
Breaking Biology News(10 mins):Half of global wildlife lost, says new WWF report 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... When a study in her lab showed that mate ... in the activity of an enzyme that promotes HDL ... Illinois scientist Elvira de Mejia headed for Argentina where ... centuries. She returned with a five-year agreement signed ...
... taking place in London on Thursday 25 and Friday ... natural scientists with what is becoming the worlds largest ... genomics - the Economic and Social Research Council (ESRC) ... are often described as the ,genetic information, that makes ...
... 17, 2007 Just in time for Halloween, researchers are ... social stress, in an article scheduled for publication in the ... adults alike gear up for the anticipation and excitement of ... our inherent fear of the dark. Grillon ...
Cached Biology News:More on mate tea: lower cholesterol and an international agreement 2From GM farm animals to embryonic stem cell research 2From GM farm animals to embryonic stem cell research 3Social stress + darkness = increased anxiety 2
... GenePix Pro is the industry standard microarray ... combination of imaging and analysis tools, visualizations, ... GenePix Pro is included with every GenePix ... from third-party scanners and all types of ...
... ideal instrument for budget-conscious labs that want to ... Get Applied Biosystems proven PCR performance at ... without sacrificing results. Enhance productivity with ... Can Afford The Applied Biosystems 2720 ...
... Sigma-Genosys offers custom peptide synthesis with a wide ... best fit your research needs. Purity: ... Yield: 2mg-1g Sequence Length: ... Biotin, Fluorescein, N-acetylation, C-amidation, phosphorylation, D-amino acids, MAPs, ...
... handling system from Molecular Devices provides precise ... instrument. The system handles a variety of ... 384- and 1536-welland is the first to ... been optimized to dispense from four different ...
Biology Products: